157 related articles for article (PubMed ID: 16729027)
1. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death.
Boesten LS; Zadelaar SM; De Clercq S; Francoz S; van Nieuwkoop A; Biessen EA; Hofmann F; Feil S; Feil R; Jochemsen AG; Zurcher C; Havekes LM; van Vlijmen BJ; Marine JC
Cell Death Differ; 2006 Dec; 13(12):2089-98. PubMed ID: 16729027
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G
Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690
[TBL] [Abstract][Full Text] [Related]
3. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
4. Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development.
Zhang Q; He X; Chen L; Zhang C; Gao X; Yang Z; Liu G
J Pathol; 2012 Nov; 228(3):416-28. PubMed ID: 22821713
[TBL] [Abstract][Full Text] [Related]
5. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
6. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
7. Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity.
Giglio S; Mancini F; Pellegrino M; Di Conza G; Puxeddu E; Sacchi A; Pontecorvi A; Moretti F
Oncogene; 2010 Nov; 29(44):5935-45. PubMed ID: 20697359
[TBL] [Abstract][Full Text] [Related]
8. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
9. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
10. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
11. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
[TBL] [Abstract][Full Text] [Related]
12. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
13. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
14. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Fernandez-Garcia B; Lozano G
Circulation; 2007 Jun; 115(23):2925-30. PubMed ID: 17533180
[TBL] [Abstract][Full Text] [Related]
15. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
17. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
18. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
19. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
Chavez-Reyes A; Parant JM; Amelse LL; de Oca Luna RM; Korsmeyer SJ; Lozano G
Cancer Res; 2003 Dec; 63(24):8664-9. PubMed ID: 14695178
[TBL] [Abstract][Full Text] [Related]
20. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]